Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

SCHOTT Doubles its Production Capacity for SCHOTT TopPac® Polymer Syringes

Published: Tuesday, April 30, 2013
Last Updated: Monday, April 29, 2013
Bookmark and Share
Company to offer customers a greater degree of flexibility and ensure supply security.

To address the increasing global demand for prefillable polymer syringes, SCHOTT is currently expanding its manufacturing capacity for small size (1 to 10 ml) SCHOTT TopPac® syringes.

A new production line installed at the SCHOTT site in St. Gallen, Switzerland, expanded the existing production capacity by 100% from April onwards.

This enables SCHOTT to offer customers a greater degree of flexibility and ensure supply security.

SCHOTT is a pioneer in establishing the SCHOTT TopPac® product range as ready-to-fill syringes, which are made of Cyclic Olefin Copolymer (COC).

Over the past 15 years, SCHOTT made significant investments to develop and industrialize COC material for pharmaceutical containers for injectable drugs.

COC is an inert material and the SCHOTT TopPac® syringe system is designed to be compatible with a broad range of drugs. The excellent barrier properties of the SCHOTT TopPac® syringe system allow long term storage of drugs even in small syringe sizes.

In addition, SCHOTT TopPac® syringes have a glass-like transparency, and are break resistant and lightweight.

SCHOTT TopPac® syringes are available in the range from 1ml to 50ml with cross linked silicone for optimal functionality.

Pharmaceutical companies benefit from the fact that SCHOTT TopPac® syringes are manufactured in clean rooms with a fully automated process starting from injection-molding to the final packaging in nest and tub. The syringes are sterilized and are ready for aseptic filling operations.

SCHOTT intends to achieve further growth in the field of polymer and glass syringes and also underscores its commitment to offer ideal product solutions to pharmaceutical companies - today and tomorrow.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SCHOTT Announces Major Expansion of Pharmaceutical Packaging Manufacturing in Russia
Capacity to expand by more than 50 percent / Consistent investment strategy helps customers achieve growth and quality objectives.
Monday, November 26, 2012
Scientific News
Envigo Rat Models Proven to be Susceptible to Intra-Vaginal HSV-2 Infection and Protectable
Scientific findings establish the effectiveness of new approach to investigate the protective effects of vaccine candidates and anti-viral microbodies and to study asymptomatic primary genital HSV-2 infection.
Drug that Activates Innate Immune System Identified
Researchers from the institute have identified a drug, which is straightforward to synthesize and to couple to antigens that induce an immune response and may prove useful in the generation of vaccines.
Valvena, GSK Sign New R&D Collaboration
Valneva to supply process development services for EB66® -based Influenza vaccines.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Protein Protects Against Flu in Mice
The engineered molecule doesn’t provoke inflammation and may hail a new class of antivirals.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!